KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amgen (AMGN) Equity Income (2020 - 2025)

Amgen has reported Equity Income over the past 6 years, most recently at $10.0 million for Q3 2025.

  • Quarterly results put Equity Income at $10.0 million for Q3 2025, up 135.71% from a year ago — trailing twelve months through Sep 2025 was -$20.0 million (down 17.65% YoY), and the annual figure for FY2024 was $10.0 million, up 190.91%.
  • Equity Income for Q3 2025 was $10.0 million at Amgen, up from -$18.0 million in the prior quarter.
  • Over the last five years, Equity Income for AMGN hit a ceiling of $97.0 million in Q4 2021 and a floor of -$305.0 million in Q1 2022.
  • Median Equity Income over the past 5 years was -$11.0 million (2025), compared with a mean of -$31.0 million.
  • Biggest five-year swings in Equity Income: plummeted 671.43% in 2022 and later soared 142.86% in 2024.
  • Amgen's Equity Income stood at $97.0 million in 2021, then plummeted by 283.51% to -$178.0 million in 2022, then soared by 84.27% to -$28.0 million in 2023, then skyrocketed by 96.43% to -$1.0 million in 2024, then surged by 1100.0% to $10.0 million in 2025.
  • The last three reported values for Equity Income were $10.0 million (Q3 2025), -$18.0 million (Q2 2025), and -$11.0 million (Q1 2025) per Business Quant data.